Opening book details…
Can I read Magnetic resonance imaging‐guided transurethral ultrasound ablation for benign prostatic hyperplasia: 12‐month clinical outcomes of a phase I study on EtoBox?
Magnetic resonance imaging‐guided transurethral ultrasound ablation for benign prostatic hyperplasia: 12‐month clinical outcomes of a phase I study by Antti Viitala; Mikael Anttinen; Cameron Wright; Ilari Virtanen; Pietari Mäkelä; Topi Hovinen; Teija Sainio; Jani Saunavaara; Pekka Taimen; Roberto Blanco Sequeiros; Peter J. Boström is a Medicine article available to read on EtoBox.
What is Magnetic resonance imaging‐guided transurethral ultrasound ablation for benign prostatic hyperplasia: 12‐month clinical outcomes of a phase I study about?
## Objectives To investigate the safety and feasibility of magnetic resonance imaging (MRI)-guided transurethral ultrasound ablation (TULSA) for the treatment of benign prostatic obstruction (BPO). ## Patients and methods An investigator-initiated, prospective, registered (NCT03350529), phase I study enrolled men with lower urinary tract symptoms due to benign prostatic hyperplasia in need of surgical intervention. Patients were followed for 12 months after TULSA. Uroflowmetry, prostate-specific antigen (PSA) level, and a comprehensive set of functional questionnaires including the Expanded Prostate cancer Index Composite-26, International Prostate Symptom Score (IPSS) and five-item version of the International Index of Erectile Function were obtained at baseline and every 3 months afterwards. MRI was obtained at baseline, and at 3 and 12 months after TULSA. Medication use before and after TULSA were recorded. Adverse events (AEs) were reported using the Clavien-Dindo classification. ## Results A total of 10 men underwent TULSA with no severe AEs encountered. The baseline median (interquartile range [IQR]) age and prostate volume were 68 (63-72) years and 53 (45-66) mL, respectivel
Who reads Magnetic resonance imaging‐guided transurethral ultrasound ablation for benign prostatic hyperplasia: 12‐month clinical outcomes of a phase I study?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Antti Viitala; Mikael Anttinen; Cameron Wright; Ilari Virtanen; Pietari Mäkelä; Topi Hovinen; Teija Sainio; Jani Saunavaara; Pekka Taimen; Roberto Blanco Sequeiros; Peter J. Boström
- Publisher
- Wiley
- Published
- 2022
- Language
- EN
- Field
- Medicine (Health Sciences)